# Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)

> **NCT04326283** · PHASE1,PHASE2 · TERMINATED · sponsor: **Genuv Inc.** · enrollment: 23 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Trametinib (0.5 mg)
- **DRUG:** Trametinib (1 mg)
- **DRUG:** Riluzole (100 mg)

## Key facts

- **NCT ID:** NCT04326283
- **Lead sponsor:** Genuv Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-02
- **Primary completion:** 2023-04-28
- **Final completion:** 2023-04-28
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Terminated as it is considered that necessary data have been collected
- **Last updated:** 2023-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04326283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04326283, "Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04326283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*